Saturday, July 11, 2026

Drug profile · INN

quinapril hydrochloride

quinapril hydrochloride (QUINAPRIL HYDROCHLORIDE) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — quinapril hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

quinapril hydrochloride (QUINAPRIL HYDROCHLORIDE) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN quinapril hydrochloride
Brand QUINAPRIL HYDROCHLORIDE
Mechanism Angiotensin-converting enzyme inhibitor
Target Angiotensin-converting enzyme
Route ORAL
Formulation TABLET

Mechanism of action

Angiotensin-converting enzyme inhibitor

Primary target: Angiotensin-converting enzyme

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. benazepril hydrochloride Angiotensin-converting enzyme inhibitor
  2. captopril Angiotensin-converting enzyme inhibitor
  3. enalapril maleate Cardiovascular system (C09)
  4. fosinopril sodium Angiotensin-converting enzyme inhibitor
  5. lisinopril Angiotensin-converting enzyme inhibitor
  6. moexipril hydrochloride Angiotensin-converting enzyme inhibitor

Frequently asked questions

What is quinapril hydrochloride?

quinapril hydrochloride (QUINAPRIL HYDROCHLORIDE) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for quinapril hydrochloride?

QUINAPRIL HYDROCHLORIDE is a marketed brand name for quinapril hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of quinapril hydrochloride?

quinapril hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.